Copyright
©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 641-651
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.641
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.641
Figure 3 Nivolumab treatment continuity in patients who developed hypothyroidism.
Treatment continuity in patients who developed hypothyroidism was significantly longer than in those who did not develop hypothyroidism (n = 104, median not reached vs 7 times administration, P = 0.010).
- Citation: Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651
- URL: https://www.wjgnet.com/2218-4333/full/v13/i7/641.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i7.641